KEAP1 and lung carcinoma: In addition, by analyzing the TCGA human lung cancer dataset, we found that the advanced‐stage tumors (clinical stage IV disease) were significantly enriched for the human KEAP1‐mutant transcriptional signature (Figure 5J), and core SOX9 target genes were significantly upregulated in tumors from advanced stage (Figure 5K).